GlaxoSmithKline Ventolin HFA Inhalers Recall: Defective Delivery System Risk
GlaxoSmithKline recalls Ventolin HFA inhalers with leak rate issues. Affected units have specific lot numbers and expiration dates. Consumers should contact for remedy details.
Lower-risk recall
Defective Delivery System: Elevated number of units with out of specification results for leak rate.
Contact the company
What happened, in plain English
GlaxoSmithKline is recalling Ventolin HFA inhalers that may have a defective delivery system causing elevated leak rates. This could lead to inconsistent medication delivery, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/41794-glaxosmithkline-ventolin-hfa-inhalers-recall-defective-delivery-system-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41794-glaxosmithkline-ventolin-hfa-inhalers-recall-defective-delivery-system-risk · Updated October 8, 2026 · FDA enforcement record: FDA #D-0626-2017
Cite this page
“GlaxoSmithKline Ventolin HFA Inhalers Recall: Defective Delivery System Risk.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41794-glaxosmithkline-ventolin-hfa-inhalers-recall-defective-delivery-system-risk. Based on FDA recall #D-0626-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0626-2017%22&limit=1).
Why it’s dangerous
The inhalers may leak more than specified, leading to inconsistent medication delivery. This could result in reduced effectiveness of the treatment for respiratory conditions.
Who’s affected
People with asthma or respiratory conditions prescribed Ventolin HFA inhalers. Those using the affected lot numbers are most at risk.
How to tell if you have this one
Check the lot numbers: 6ZP9848 (exp 03/18), 6ZP0003, 6ZP9944 (exp 04/18). The product is a prescription inhaler with specific net weight and expiration dates.
- Brand
GlaxoSmithKline- Category
Drug
What to do — step by step
Check Product Details
Identify the lot number and expiration date on the inhaler's packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 21 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0626-2017 (March 22, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0626-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.